Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
These abstracts report on the company's three lead drug candidates, including olverembatinib
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Subscribe To Our Newsletter & Stay Updated
